462 related articles for article (PubMed ID: 32340837)
21. Covid-19 treatment update: follow the scientific evidence.
Becker RC
J Thromb Thrombolysis; 2020 Jul; 50(1):43-53. PubMed ID: 32338320
[No Abstract] [Full Text] [Related]
22. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M
Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906
[No Abstract] [Full Text] [Related]
23. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.
Andreani J; Le Bideau M; Duflot I; Jardot P; Rolland C; Boxberger M; Wurtz N; Rolain JM; Colson P; La Scola B; Raoult D
Microb Pathog; 2020 Aug; 145():104228. PubMed ID: 32344177
[TBL] [Abstract][Full Text] [Related]
24. Chloroquine and hydroxychloroquine in covid-19.
Ferner RE; Aronson JK
BMJ; 2020 Apr; 369():m1432. PubMed ID: 32269046
[No Abstract] [Full Text] [Related]
25. Auditory Cinchonism in COVID Era.
Saniasiaya J; Kulasegarah J
Ear Nose Throat J; 2020 Nov; 99(9):597-598. PubMed ID: 32744901
[No Abstract] [Full Text] [Related]
26. Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
Aggarwal G; Henry BM; Aggarwal S; Bangalore S
Am J Cardiol; 2020 Aug; 128():147-150. PubMed ID: 32425199
[TBL] [Abstract][Full Text] [Related]
27. The COVIRL-001 Trial: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non- critical, SARS-CoV-2 PCR-positive population not requiring immediate resuscitation or ventilation but who have evidence of clinical decline: A structured summary of a study protocol for a randomised controlled trial.
Feeney E; Wallace D; Cotter A; Tinago W; McCarthy C; Keane D; Hussain R; Alvarez Barco E; Doran P; Mallon P
Trials; 2020 May; 21(1):430. PubMed ID: 32450915
[No Abstract] [Full Text] [Related]
28. COVID-19 and hydroxychloroquine: Is the wonder drug failing?
Paliani U; Cardona A
Eur J Intern Med; 2020 Aug; 78():1-3. PubMed ID: 32553587
[No Abstract] [Full Text] [Related]
29. Silencing of immune activation with methotrexate in patients with COVID-19.
Safavi F; Nath A
J Neurol Sci; 2020 Aug; 415():116942. PubMed ID: 32471659
[No Abstract] [Full Text] [Related]
30. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Gautret P; Lagier JC; Parola P; Hoang VT; Meddeb L; Mailhe M; Doudier B; Courjon J; Giordanengo V; Vieira VE; Tissot Dupont H; Honoré S; Colson P; Chabrière E; La Scola B; Rolain JM; Brouqui P; Raoult D
Int J Antimicrob Agents; 2020 Jul; 56(1):105949. PubMed ID: 32205204
[TBL] [Abstract][Full Text] [Related]
31. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
Pani A; Lauriola M; Romandini A; Scaglione F
Int J Antimicrob Agents; 2020 Aug; 56(2):106053. PubMed ID: 32534189
[TBL] [Abstract][Full Text] [Related]
32. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.
Okour M; Al-Kofahi M; Austin D
J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):187-188. PubMed ID: 32405664
[No Abstract] [Full Text] [Related]
33. Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
Mégarbane B; Scherrmann JM
J Clin Pharmacol; 2020 Jul; 60(7):808-814. PubMed ID: 32434282
[No Abstract] [Full Text] [Related]
34. Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19.
Sun X; Ni Y; Zhang M
Emerg Microbes Infect; 2020 Dec; 9(1):830-832. PubMed ID: 32338155
[TBL] [Abstract][Full Text] [Related]
35. COVID-19: Small-Molecule Clinical Trials Landscape.
Ferreira LLG; Andricopulo AD
Curr Top Med Chem; 2020; 20(18):1577-1580. PubMed ID: 32862824
[No Abstract] [Full Text] [Related]
36. Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
Baralić K; Jorgovanović D; Živančević K; Antonijević Miljaković E; Antonijević B; Buha Djordjevic A; Ćurčić M; Đukić-Ćosić D
Toxicol Appl Pharmacol; 2020 Nov; 406():115237. PubMed ID: 32920000
[TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2: a time for clear and immediate action.
Poland GA
Lancet Infect Dis; 2020 May; 20(5):531-532. PubMed ID: 32243818
[No Abstract] [Full Text] [Related]
38. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rueegg CS; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Nat Commun; 2020 Oct; 11(1):5284. PubMed ID: 33082342
[TBL] [Abstract][Full Text] [Related]
39. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic.
Brufsky A
J Med Virol; 2020 Jul; 92(7):770-775. PubMed ID: 32293710
[TBL] [Abstract][Full Text] [Related]
40. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
